Market Research

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

Best Price Guarantee Length Publisher Published Date SKU
from $3,840 160 Pages Allied Market Research October, 2022 ALMR17651686
Best Price Guarantee
Price from $3,840
Length 160 Pages
Publisher Allied Market Research
Published Date October, 2022
SKU ALMR17651686

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth. 

Key Market Segments

By Product

Injectables
Oral antidiabetic Drugs

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

ASTRAZENECA PLC
BOEHRINGER INGELHEIM GMBH
ELI LILLY AND COMPANY
GLAXOSMITHKLINE PLC
NOVARTIS AG
NOVO NORDISK
SANOFI S.A.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
johnson and johnson md&d
MERCK and CO., INC.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Injectables
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral antidiabetic Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Product
5.2.3 North America Market size and forecast, by country
5.2.3.1 U.S.
5.2.3.1.1 Market size and forecast, by Product
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Product
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Product
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Product
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Product
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Product
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Product
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Product
5.3.3.5 Spain
5.3.3.5.1 Market size and forecast, by Product
5.3.3.6 Rest of Europe
5.3.3.6.1 Market size and forecast, by Product
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Product
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 China
5.4.3.1.1 Market size and forecast, by Product
5.4.3.2 Japan
5.4.3.2.1 Market size and forecast, by Product
5.4.3.3 India
5.4.3.3.1 Market size and forecast, by Product
5.4.3.4 Australia
5.4.3.4.1 Market size and forecast, by Product
5.4.3.5 Rest Of Asia Pacific
5.4.3.5.1 Market size and forecast, by Product
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Product
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Product
5.5.3.2 Saudi Arabia
5.5.3.2.1 Market size and forecast, by Product
5.5.3.3 South Africa
5.5.3.3.1 Market size and forecast, by Product
5.5.3.4 Rest of LAMEA
5.5.3.4.1 Market size and forecast, by Product
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 ASTRAZENECA PLC
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 BOEHRINGER INGELHEIM GMBH
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 ELI LILLY AND COMPANY
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 GLAXOSMITHKLINE PLC
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 NOVARTIS AG
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 NOVO NORDISK
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 SANOFI S.A.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 johnson and johnson md&d
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 MERCK and CO., INC.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)
TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 36.ASTRAZENECA PLC: NET SALES,
TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,
TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 46.ELI LILLY AND COMPANY: NET SALES,
TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 54.NOVARTIS AG: OPERATING SEGMENTS
TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 56.NOVARTIS AG: NET SALES,
TABLE 57.NOVARTIS AG: KEY STRATERGIES
TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 59.NOVO NORDISK: OPERATING SEGMENTS
TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 61.NOVO NORDISK: NET SALES,
TABLE 62.NOVO NORDISK: KEY STRATERGIES
TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 64.SANOFI S.A.: OPERATING SEGMENTS
TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 66.SANOFI S.A.: NET SALES,
TABLE 67.SANOFI S.A.: KEY STRATERGIES
TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,
TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 81.MERCK AND CO., INC.: NET SALES,
TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION
FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030
FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)
FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020
FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 34. TOP WINNING STRATEGIES, BY YEAR
FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 38.COMPETITIVE DASHBOARD
FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)
FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)
FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)
FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION)

$5,730
$3,840
$6,450
$9,600

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings